Agonizing over agonism: Should asthmatics turn their β-receptors on or off?

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 7, 2009, Pages 2095-2096

  Penn, Raymond B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; BETA ADRENERGIC RECEPTOR; NADOLOL; SALBUTAMOL;

ASTHMA; BRONCHOSPASM; CONGESTIVE CARDIOMYOPATHY; DRUG SAFETY; HEART MUSCLE CONTRACTILITY; MEDICAL RESEARCH; NONHUMAN; NOTE; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ASTHMA; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; RISK; SIGNAL TRANSDUCTION;

EID: 60549104043     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812935106     Document Type: Note

References (16)

1. Brittain RT, Farmer JB, Jack D, Martin LE, Simpson WT (1968) Alpha-[(t-butylamino)methyl]-4-hydroxy-m-xylene-alpha1, alpha3-diol (AH.3365): A selective betaadrenergic stimulant. Nature 219:862-863.
2. Sears MR (2002) Adverse effects of beta-agonists. J Allergy Clin Immunol 110:S322-S328.
3. Nelson HS (2006) Is there a problem with inhaled long-acting beta-adrenergic agonists? J Allergy Clin Immunol 117:3-16.
4. 2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci USA 106:2435-2440.
5. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022-1036.
6. Liggett SB (2001) β-Adrenergic receptors in the failing heart: the good, the bad, and the unknown. J Clin Invest 107:947-948.
7. Penn RB (2008) Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch Pharmacol 378:149-169.
8. Callaerts-Vegh Z, et al. (2004) Effects of acute and chronic administration of β-adrenoceptor ligands on airway function in amurine model of asthma. Proc Natl Acad Sci USA 101:4948-4953.
9. Hanania NA, et al. (2007) The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study. Pulm Pharmacol Ther 21:134-141.
10. Nguyen LP, et al. (2008) Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 38:256-262.
11. Loza MJ, Peters SP, Foster S, Khan IU, Penn RB (2007) β-Agonist enhances type 2 T-cell survival and accumulation. J Allergy Clin Immunol 119:235-244.
12. Wisler JW, et al. (2007) A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci USA 104:16657-16662.
13. Zaid G, Beall GN (1966) Bronchial response to beta-adrenergic blockade. N Engl J Med 275:580-584.
14. Salpeter S, Ormiston T, Salpeter E (2002) Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev CD002992.
15. Ind PW, Dixon CM, Fuller RW, Barnes PJ (1989) Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis 139:1390-1394.
16. Lin R, et al. (2007) Changes in beta2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther 21:115-124.